PSN-375963

• 产品号: P0028
• CAS号: 388575-52-8
• 分子式: C17H23N3O
• 分子量: 285.38402
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: PSN-375963
• IUPAC标准名: 4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]pyridine
• IUPAC传统名: 4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]pyridine
• 别名: 4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridine

产品登记号

• MDL号: MFCD01829706
• CAS号: 388575-52-8

产品性质

• Empirical Formula (Hill Notation): C17H23N3O
• 纯度: ≥98% (HPLC)
• 外观: white to off-white powder
• 溶解度: DMSO: >10 mg/mL
• 保存温度: -20°C
• 德国WGK号: nwg

产品详细信息

详细说明 (English)

Biochem/physiol Actions
PSN-375963 is a GPR119 partial agonist. GPR119 is an orphan GPCR, expressed predominantly in pancreas and GI tract, that has been characterized. Its endogenous ligands are oleoylethanolamide (OEA) and oleoyl-lysophosphatidylcholine, lipid signaling molecules that regulate food intake and body weight. OEA decreases food intake, so GPR119 agonists are potential therapies for obesity. Initial studies showed that PSN-375963 has similar potency and partial efficacy compared to OEA. Further studies revealed that although OEA and PSN-375963 are GPR119 agonists, they have divergent effects on insulin secretion, calcium signaling, and cAMP production.

详细说明 (简体中文)

Biochem/physiol Actions
PSN-375963 is a GPR119 partial agonist. GPR119 is an orphan GPCR, expressed predominantly in pancreas and GI tract, that has been characterized. Its endogenous ligands are oleoylethanolamide (OEA) and oleoyl-lysophosphatidylcholine, lipid signaling molecules that regulate food intake and body weight. OEA decreases food intake, so GPR119 agonists are potential therapies for obesity. Initial studies showed that PSN-375963 has similar potency and partial efficacy compared to OEA. Further studies revealed that although OEA and PSN-375963 are GPR119 agonists, they have divergent effects on insulin secretion, calcium signaling, and cAMP production.